TARSUS PHARMACEUTICALS, INC. Other Current Liabilities
TARSUS PHARMACEUTICALS, INC. (TARS) had Other Current Liabilities of $25.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Liabilities, Current $25.43M.
- 2026-03-31: Other Liabilities, Current $32.50M.
- 2025-12-31: Other Liabilities, Current $22.18M.
- 2024-12-31: Other Liabilities, Current $18.32M.
| Period end | Other Liabilities, Current |
|---|---|
| 2026-06-30 | $25.43M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $32.50M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $22.18M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $18.32M 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |